1180675-98-2

Upstream product

• 1005514-85-1 3-amino-5-pentafluorosulfanylbenzoic acid 
• 852469-45-5 3-nitro-5-(pentafluoro-λ⁶-sulfanyl)benzoic acid 
• 833-96-5 3-(pentafluoro-λ⁶-sulphanyl)benzoic acid 

Downstream Products

• 1211541-62-6 methyl 3-bromo-5-(pentafluoro-λ⁶-sulphanyl)benzoate 
• 1240257-00-4 3-methyl-5-(pentafluoro-λ⁶-sulphanyl)benzoic acid 
• 1448317-66-5 3-(methylsulphonyl)-5-(pentafluoro-λ⁶-sulphanyl)benzoic acid 
• 1448317-60-9 3-(2-methyl-1H-imidazol-1-yl)-5-(pentafluoro-λ⁶-sulphanyl)benzoic acid 
• 1448317-58-5 3-cyano-5-(pentafluoro-λ⁶-sulphanyl)benzoic acid 
• 1448317-52-9 3-(morpholin-4-yl)-5-(pentafluoro-λ⁶-sulphanyl)benzoic acid 
• 1448317-49-4 3-[4-(tert-butoxycarbonyl)piperazin-1-yl]-5-(pentafluoro-λ⁶-sulphanyl)benzoic acid 
• 1448316-45-7 N-{2,4-dimethyl-5-[6-(pyridin-3-yl)-1H-imidazo[1,2-b]pyrazol-1-yl]phenyl}-3-(methoxymethyl)-5-(pentafluoro-λ⁶-sulphanyl)benzamide 
• 1448316-43-5 3-({2,4-dimethyl-5-[6-(pyridin-3-yl)-1H-imidazo[1,2-b]pyrazol-1-yl]phenyl}carbamoyl)-5-(penta-fluoro-λ⁶-sulphanyl)benzoic acid 
• 1448316-17-3 3-cyano-N-{2-hydroxy-3-[6-(pyridin-3-yl)-1H-imidazo[1,2-b]pyrazol-1-yl]phenyl}-5-(pentafluoro-λ⁶-sulphanyl)benzamide 
• 1448316-14-0 3-cyano-N-{2-methyl-3-[6-(pyridin-3-yl)-1H-imidazo[1,2-b]pyrazol-1-yl]phenyl}-5-(pentafluoro-λ⁶-sulphanyl)benzamide 
• 1448316-11-7 3-cyano-N-{2-methyl-5-[6-(pyridin-3-yl)-1H-imidazo[1,2-b]pyrazol-1-yl]phenyl}-3-(pentafluoro-λ⁶-sulphanyl)benzamide 
• 1448315-68-1 N-{4-methyl-3-[6-(pyridin-3-yl)-1H-imidazo[1,2-b]pyrazol-1-yl]phenyl}-3-(pentafluoro-λ⁶-sulphanyl)-5-(piperazin-1-ylmethyl)benzamide 
• 1448315-61-4 3-cyano-N-{4-methyl-3-[6-(pyridin-3-yl)-1H-imidazo[1,2-b]pyrazol-1-yl]phenyl}-5-(pentafluoro-λ⁶-sulphanyl)benzamide 

Relevant academic research and scientific papers

ALPHAvBETA1 INTEGRIN ANTAGONISTS

The present disclosure provides pharmaceutical agents, including those of the formula: (I) wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents are also provided. The compounds may be used for the inhibition or antagonism of integrins ανβ1 and/or α5β1. In some embodiments, the compounds provided herein exhibit reduced inhibitory or antagonistic activity of integrins ανβ3, ανβ5, ανβ6, ανβ8, and/or αIIbβ3.

Substituted phenylimidazopyrazoles and their use

The present application relates to novel 1-phenyl-1H-imidazo[1,2-b]pyrazole derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular angiogenic disorders and hyperproliferative disorders, where neovascularization plays a role, such as, for example, neoplastic disorders and tumour disorders. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.

SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS

The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R9, Ar, Q1, Q2 and Q3 are each as defined below. The compounds of the formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of the formula I and to the use thereof as a medicament.